Markets
ABT

Novartis Announces Positive Data on Arthritis Drug Cosentyx

NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis.

The results were published in the New England Journal of Medicine .

The multi-center, randomized, placebo-controlled phase III study was conducted to evaluate the efficacy of Cosentyx in IL-17A inhibition in patients suffering from psoriatic arthritis. The study met its primary endpoint as Cosentyx demonstrated a 20% reduction in the American College of Rheumatology response criteria (ACR 20) at the end of week 24. The study showed that treatment with Cosentyx resulted in rapid and significant clinical improvements versus placebo.

Moreover, Cosentyx met all secondary endpoints, including improvements in skin and joint diseases, and joint structural damage progression. It was seen that approximately half of the patients in both Cosentyx-treated dose groups (150-mg and 75-mg) achieved an ACR 20 response as compared to only 17.3% in the placebo arm.

We remind investors that Cosentyx (at a dose of 300 mg) was approved in Europe as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adult patients in Jan 2015. The drug was also approved in the U.S. as a treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy (light therapy).

Novartis made regulatory submissions across the world for the indication of psoriatic arthritis and ankylosing spondylitis. A potential label expansion of the drug will further boost its growth prospects.

We also note that Novartis had undertaken a series of actions to reorganize its portfolio in 2014 in order to focus on its core businesses of pharmaceuticals, eye care and generics. However, Novartis is expected to face headwinds this year in the form of generic competition for some products as well as negative currency movement.

Novartis currently carries a Zacks Rank #4 (Sell). Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

ABBOTT LABS (ABT): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABT NVS NVO ABBV

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More